Prostate cancer is the most commonly diagnosed cancer in men.
At present, patients are selected for prostate biopsy on the basis of age, serum prostate specific antigen (PSA), and prostatic digital rectal examination (DRE) findings. However, due to limitations in the use of PSA and DRE, many patients undergo unnecessary prostate biopsy. A further problem arises as many patients are diagnosed and treated for indolent disease. This review of the literature highlights the strengths and weaknesses of existing methods of prebiopsy risk stratification and evaluates promising serum, urine, and radiologic prostate cancer biomarkers, which may improve risk stratification for prostate biopsy in the future.
Written by:
Pal RP, Maitra NU, Mellon JK, Khan MA. Are you the author?
University Hospitals of Leicester NHS Trust, Department of Urology, Leicester General Hospital, Leicester, LE5 4PW, UK.
Reference: Urol Oncol. 2012 Jul 11. Epub ahead of print.
doi: 10.1016/j.urolonc.2012.05.012
PubMed Abstract
PMID: 22795499
UroToday.com Prostate Cancer Section
